Medical radiation shielding market seen reaching $3.39 billion by 2035

Market Research Future says the global medical radiation shielding market will grow from $1.83 billion in 2026 to $3.39 billion by 2035, driven by rising cancer cases, more proton therapy buildouts and tighter safety rules. The forecast points to durable demand for shielding in hospitals, imaging centers and radiation therapy rooms worldwide.

Why it matters: - The market is tied to core cancer care infrastructure, not discretionary spending. - More cancer diagnoses, more imaging rooms and more radiation therapy vaults translate into steady demand for shielding materials and installation. - Regulatory upgrades can force hospitals and treatment centers to replace or reinforce existing barriers.

What happened: - Market Research Future forecast the global medical radiation shielding market at $1.83 billion in 2026 and $3.39 billion by 2035. - The report put the 2026-2035 compound annual growth rate at 7.1%. - The market base was estimated at $1.71 billion in 2025. - The report was published June 25, 2026. - A free sample and customization request are available.

The details: - Rising global cancer incidence is the main demand driver. - The WHO Global Cancer Observatory forecasts new cancer diagnoses will rise from 20 million in 2022 to about 35 million annually by 2050. - India's cancer incidence is projected to climb 12.8% by 2030. - Every new linear accelerator vault, brachytherapy suite or PET-CT room needs purpose-built shielding. - Proton and heavy ion therapy centers are raising shielding spend per project. - The Particle Therapy Co-Operative Group reported 127 operational proton/carbon-ion centers worldwide by mid-2025, with 42 more under construction. - China has approved 15 new proton centers under its 14th Five-Year Plan for medical infrastructure. - A proton treatment room can require concrete-and-steel shielding walls exceeding 2 meters thick. - The report also cited tighter rules, including the EU's Basic Safety Standards Directive and updated U.S. Nuclear Regulatory Commission guidelines. - European data cited in the report show that preventing one radiation overexposure event can save about $50,000 to $80,000 in litigation and remediation costs.

Between the lines: - Lead-based shielding remains the default because hospitals already trust the material and regulators accept it. - Non-lead composites are growing faster because environmental rules are pushing healthcare builders away from lead. - The biggest-value contracts are shifting toward proton and heavy ion therapy sites, where shielding needs are larger and more customized. - The report's regional split suggests Asia-Pacific is becoming the main growth engine while North America remains the largest revenue pool. - Competitive advantages are moving toward companies that can deliver turnkey engineering, regulatory support and proprietary non-lead products.

What's next: - Radiation therapy demand should keep rising as oncology facilities expand through 2035. - The report expects precision radiopharmaceutical theranostics and PSMA-PET-driven workflows to reshape shielding design later in the decade. - The DOE's $214 million isotope investment is expected to support domestic actinium-225 supply growth. - Machine-learning and generative design tools may reduce shielding material use by 10% to 15% while maintaining dose compliance. - The fastest growth is expected in Asia-Pacific, ambulatory surgery centers, non-lead composite shielding and radiation therapy applications.

The bottom line: - Medical radiation shielding is becoming a long-duration infrastructure market, with cancer care expansion, compliance upgrades and advanced therapy buildouts driving demand through 2035.